In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

Abstract

In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.

• Authors: L A Collins, G M Eliopoulos, C B Wennersten, M J Ferraro, R C Moellering Jr
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 37 Issue 6 Pg. 1364-6 (Jun 1993) ISSN: 0066-4804 [Print] United States
• PMID: 8328787 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Depsipeptides
• Peptides, Cyclic
• ramoplanin
• Vancomycin

Topics

• Anti-Bacterial Agents (pharmacology)
• Depsipeptides
• Drug Resistance, Microbial
• Enterococcus (drug effects)
• Gram-Positive Bacteria (drug effects)
• Humans
• Kinetics
• Microbial Sensitivity Tests
• Peptides, Cyclic
• Vancomycin (pharmacology)